Target- |
Mechanism- |
|
Originator Org.- |
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 1, First-in-Human, Single-center, Randomized, Double-masked, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of MDI-1228_mesylate Ophthalmic Solution by Local Instillation in Adult Healthy Volunteers
The main goal of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics (PK) profiles* of MDI-1228_mesylate Ophthalmic Solution in healthy adult participants.
Participants will receive either of the following treatment:
* MDI-1228_mesylate Ophthalmic Solution, or
* Placebo**
Researchers will observe any changes in health (if any) in participants receiving the study treatment to evaluate the safety and tolerability*** of the study drug. Researchers will also collect several blood samples from participants to study PK profiles of the drug.
Note:
*PK profiles: how the drug interacts with the body. **placebo: a harmless substance that contains no active agents. ***tolerability: how well you can tolerate the drug.
100 Clinical Results associated with Shanghai Meiyinnuo Pharmaceutical Technology Co., Ltd.
0 Patents (Medical) associated with Shanghai Meiyinnuo Pharmaceutical Technology Co., Ltd.
100 Deals associated with Shanghai Meiyinnuo Pharmaceutical Technology Co., Ltd.
100 Translational Medicine associated with Shanghai Meiyinnuo Pharmaceutical Technology Co., Ltd.